Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × luspatercept × Myeloid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1 Classical hematology 1

Conditions

Myelodysplastic Syndromes 1 Anemia 1

Interventions

nilotinib 6 bosutinib 4 asciminib 3 Imatinib Mesylate 3 Decitabine 3 decitabine and cedazuridine drug combination 2 cedazuridine 2 avapritinib 2 Dasatinib 2 treosulfan 1 tagraxofusp 1 pemigatinib 1 luspatercept 1 ivosidenib 1 imetelstat 1 glasdegib 1 enasidenib 1 GRN163L peptide 1 Emapalumab 1 Daunorubicin 1 Cytarabine 1 Busulfan 1 Azacitidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02631070 2021-12-17

MEDALIST

Celgene

Phase 3 Completed

229 enrolled 36 charts 2 FDA

Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon ⚡